Immune ageing in health and disease

Immune ageing in health and disease - Immune ageing in health and disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39532

Enrollment

300

Registered

2013-07-17

Start date

2012-11-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gezonde veroudering en ongezonde veroudering/frailty ageing and frailty

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Group 1: Healthy young donors 1. Having no chronic diseases 2. Healthy according to SENIEUR protocol 3. Not-frail according to frailty instruments (Fried) 4. Age 19-39 years 5. Being able to give informed consent;Group 2: Healthy intermediate-age donors 1. Having no chronic diseases 2. Healthy according to SENIEUR protocol 3. Not-frail according to frailty instruments (Fried) 4. Age 40-60 years 5. Being able to give informed consent;Group 3: Non-frail, SENIEUR elderly donors 1. Healthy according to SENIEUR protocol 2. Not-frail according to frailty instruments (Fried, TFI, GFI) 3. Age >= 60 years 4. Being able to give informed consent;Group 4: Non-frail, non-SENIEUR elderly donors 1. Not fully healthy according to SENIEUR protocol 2. Not-frail according to frailty instruments (Fried, TFI, GFI) 3. Age >= 60 years 4. Being able to give informed consent;Group 5: Low-Frail, non-SENIEUR elderly donors 1. Not fully healthy according to SENIEUR protocol 2. Low/intermediate frail according to frailty instruments (Fried, TFI, GFI) 3. Age >= 60 years 4. Being able to give informed consent;Group 6: High-Frail, non-SENIEUR elderly donors 1. Not healthy according to SENIEUR protocol 2. High or fully frail according to frailty instruments (Fried, TFI, GFI) 3. Age >= 60 years 4. Being able to give informed consent

Exclusion criteria

Exclusion criteria: In general: 1. No informed consent 2. Clinical signs of severe anaemia, or persons known to have anaemia defined as a hemoglobulin level of less than 6,0 g/dL 3. Pregnancy;Non-SENIEUR elderly donors 1. Disease that has been reported to influence the immune system (active infection, inflammatory disease, malignancy, dementia, alcohol or drug abuse) 2. Drugs that have been reported to influence the immune system (corticosteroids, other immuno suppressive therapy, vaccination in prior 4 weeks)

Design outcomes

Primary

Measure	Time frame
Main study parameter/endpoint Which changes of T cell subsets (Th1/Tc1, Th2/Tc2, Th17/Tc17, regulatory T cells and senescent T cells) can be observed during healthy ageing versus unhealthy ageing.	—

Secondary

Measure	Time frame
Secondary study parameters/endpoints (if applicable) Does the immune risk phenotype apply to unhealthy, frail elderly individuals rather than healthy, non-frail elderly individuals? Is healthy ageing characterized by better maintenance of T cell function compared to unhealthy ageing? Construct validity of GFI compared to TFI and Fried. Other study parameters (if applicable) We will also determine the presence of HLA-DR4 and CMV/EBV status since these factors may influence ageing of the immune system. Biomarkers of inflamm-ageing will be assessed (such as crp and ESR and cytokine levels).	—

Measure

Time frame

Secondary study parameters/endpoints (if applicable) Does the immune risk phenotype apply to unhealthy, frail elderly individuals rather than healthy, non-frail elderly individuals? Is healthy ageing characterized by better maintenance of T cell function compared to unhealthy ageing? Construct validity of GFI compared to TFI and Fried. Other study parameters (if applicable) We will also determine the presence of HLA-DR4 and CMV/EBV status since these factors may influence ageing of the immune system. Biomarkers of inflamm-ageing will be assessed (such as crp and ESR and cytokine levels).

—

Countries

Netherlands

Outcome results